{"schema_version":"secwatch.filing_event.v1","accession":"0001087294-25-000012","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2025-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.763063+00:00","generated_at":"2026-05-17T02:57:23.486242+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cumberland Pharmaceuticals forms joint venture with RedHill to commercialize Talicia H. pylori therapy","bullets":["Cumberland and RedHill form new jointly owned company; Cumberland provides $4M in investment capital.","RedHill contributes all Talicia assets; Cumberland handles distribution and records product sales.","Talicia generated $8M net revenue in 2024; both companies equally share net revenues.","Talicia is FDA-approved for H. pylori, patent protected through 2042, with QIDP exclusivity.","Product has broad insurance coverage: 70% commercial, 60% government; CVS stocks at 1,700 pharmacies."],"urls":{"canonical":"https://secwatch.observer/filing/0001087294-25-000012","json":"https://secwatch.observer/filing/0001087294-25-000012.json","markdown":"https://secwatch.observer/filing/0001087294-25-000012.md","text":"https://secwatch.observer/filing/0001087294-25-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000108729425000012/0001087294-25-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000108729425000012/cpix-20251021.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:57:23.486242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}